Cor Vasa 2026, 68(4):478-480 | DOI: 10.33678/cor.2026.003
Ceramidy jako nové biomarkery kardiovaskulárních onemocnění.
- a International Clinical Research Center (ICRC), Brno, Česká republika
- b Lékařská fakulta Masarykovy univerzity, Brno, Česká republika
- c Kardiochirurgické centrum, Fakultní nemocnice Ostrava, Ostrava, Česká republika
- d I. interní kardioangiologická klinika, Fakultní nemocnice u sv. Anny v Brně, Brno, Česká republika
Cardiovascular disease is the leading cause of death globally. Traditional cardiovascular risk factors explain only 75% of the risk for cardiovascular disease and exposure to one or more vascular risk factors is common even in individuals who will not develop any clinical manifestations. Ceramides are a heterogeneous group of bioactive membrane sphingolipids that play specialized regulatory roles in cellular metabolism. Ceramides have been identified as novel biomarkers for cardiovascular diseases. © 2026, ČKS.
Keywords: Cardiovascular diseases, Ceramides, Risk factors, Subclinical atherosclerosis
Received: December 16, 2025; Revised: December 16, 2025; Accepted: January 13, 2026; Prepublished online: August 5, 2026; Published: August 31, 2026 Show citation
References
- Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980- 2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736-1788.
Go to original source... - Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847. Go to original source...
- Cho KI, Yu J, Hayashi T, et al. Strategies to Overcome Residual Risk During Statins Era. Circ J 2019;83:1973-1979. Go to original source...
- Makover ME, Schloss M. The very high residual degree of death and disease from atherosclerosis needs new approaches. J Clin Lipidol 2016;10:466-468. Go to original source...
- Hammerschmidt P, Brüning JC. Contribution of specific ceramides to obesity-associated metabolic diseases. Cell Mol Life Sci 2022;79:395. Go to original source...
- Stith JL, Velazquez FN, Obeid LM. Advances in determining signaling mechanisms of ceramide and role in disease. J Lipid Res 2019;60:913-918. Go to original source...
- Tarasov K, Ekroos K, Suoniemi M, et al. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab 2014;99:E45-E52. Go to original source...
- Laaksonen R, Ekroos K, Sysi-Aho M, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDLcholesterol. Eur Heart J 2016;37:1967-1976. Go to original source...
- Hilvo M, Meikle PJ, Pedersen ER, et al. Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. Eur Heart J 2020;41:371-380. Go to original source...
- Hilvo M, Wallentin L, Ghukasyan Lakic T, et al. Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy. J Am Heart Assoc 2020;9:e015258. Go to original source...
- Gui YK, Li Q, Liu L, et al. Plasma levels of ceramides relate to ischemic stroke risk and clinical severity. Brain Res Bull 2020;158:122-127. Go to original source...
- Lemaitre RN, Jensen PN, Hoofnagle A, et al. Plasma Ceramides and Sphingomyelins in Relation to Heart Failure Risk. Circ Heart Fail 2019;12:e005708. Go to original source...
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.